DAVID ALLISON to Weight Loss
This is a "connection" page, showing publications DAVID ALLISON has written about Weight Loss.
Connection Strength
6.806
-
Measurement rigor is not a substitute for design rigor in causal inference: increased physical activity does cause (modest) weight loss. Int J Obes (Lond). 2023 01; 47(1):3-4.
Score: 0.628
-
Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study'. Breast Cancer Res Treat. 2019 05; 175(1):263-264.
Score: 0.483
-
Weight Cycling Increases Longevity Compared with Sustained Obesity in Mice. Obesity (Silver Spring). 2018 11; 26(11):1733-1739.
Score: 0.474
-
Weighing the Evidence of Common Beliefs in Obesity Research. Crit Rev Food Sci Nutr. 2015; 55(14):2014-53.
Score: 0.363
-
Randomized controlled trial examining expectancy effects on the accuracy of weight measurement. Clin Obes. 2015 Feb; 5(1):38-41.
Score: 0.363
-
Energy intake and weight loss. JAMA. 2014 Dec 24-31; 312(24):2687-8.
Score: 0.361
-
Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure. Int J Obes (Lond). 2015 Aug; 39(8):1181-7.
Score: 0.358
-
Association of run-in periods with weight loss in obesity randomized controlled trials. Obes Rev. 2014 Jan; 15(1):68-73.
Score: 0.333
-
Randomized controlled trial of the Medifast 5 & 1 Plan for weight loss. Int J Obes (Lond). 2013 Dec; 37(12):1571-8.
Score: 0.322
-
Myths, presumptions, and facts about obesity. N Engl J Med. 2013 Jan 31; 368(5):446-54.
Score: 0.318
-
No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. Int J Obes (Lond). 2011 May; 35(5):652-7.
Score: 0.273
-
Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One. 2009 Aug 13; 4(8):e6624.
Score: 0.250
-
Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond). 2008 Oct; 32(10):1531-6.
Score: 0.234
-
The potential role of soyfoods in weight and adiposity reduction: an evidence-based review. Obes Rev. 2008 May; 9(3):219-35.
Score: 0.229
-
The effects of intentional weight loss as a latent variable problem. Stat Med. 2005 Mar 30; 24(6):941-54.
Score: 0.185
-
A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur J Clin Nutr. 2003 Apr; 57(4):514-22.
Score: 0.161
-
Weight loss causes increased mortality: cons. Obes Rev. 2003 Feb; 4(1):9-16.
Score: 0.159
-
Randomized trial of a novel lifestyle intervention compared with the Diabetes Prevention Program for weight loss in adult dependents of military service members. Am J Clin Nutr. 2021 10 04; 114(4):1546-1559.
Score: 0.145
-
Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding "The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial". Adv Clin Exp Med. 2019 Nov; 28(11):1569-1570.
Score: 0.127
-
Rigorous control conditions diminish treatment effects in weight loss-randomized controlled trials. Int J Obes (Lond). 2016 06; 40(6):895-8.
Score: 0.096
-
Increased fruit and vegetable intake has no discernible effect on weight loss: a systematic review and meta-analysis. Am J Clin Nutr. 2014 Aug; 100(2):567-76.
Score: 0.088
-
The effectiveness of breakfast recommendations on weight loss: a randomized controlled trial. Am J Clin Nutr. 2014 Aug; 100(2):507-13.
Score: 0.087
-
Empirical evidence does not support an association between less ambitious pre-treatment goals and better treatment outcomes: a meta-analysis. Obes Rev. 2013 Jul; 14(7):532-40.
Score: 0.081
-
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
Score: 0.073
-
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
Score: 0.073
-
Meta-analysis of studies of a specific delivery mode for a modified-carbohydrate diet. J Hum Nutr Diet. 2011 Dec; 24(6):525-35.
Score: 0.072
-
Sample size in obesity trials: patient perspective versus current practice. Med Decis Making. 2010 Jan-Feb; 30(1):68-75.
Score: 0.063
-
Effects of a reimbursement incentive on enrollment in a weight control program. Obesity (Silver Spring). 2007 Nov; 15(11):2733-8.
Score: 0.055
-
Obesity: person and population. Obesity (Silver Spring). 2006 Jul; 14 Suppl 4:156S-159S.
Score: 0.050
-
Dietary supplements in weight reduction. J Am Diet Assoc. 2005 May; 105(5 Suppl 1):S80-6.
Score: 0.046
-
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord. 2004 Nov; 28(11):1411-9.
Score: 0.045
-
Effects of outcome-driven insurance reimbursement on short-term weight control. Int J Obes Relat Metab Disord. 2003 Nov; 27(11):1423-9.
Score: 0.042
-
Treatment and prevention of obesity: what works, what doesn't work, and what might work. Lipids. 2003 Feb; 38(2):147-55.
Score: 0.040
-
Randomized controlled trial of a novel lifestyle intervention used with or without meal replacements in work sites. Obesity (Silver Spring). 2023 02; 31(2):374-389.
Score: 0.040
-
Sexual dimorphism in the energy content of weight change. Int J Obes Relat Metab Disord. 2002 Oct; 26(10):1339-48.
Score: 0.039
-
Novel mathematical models for investigating topics in obesity. Adv Nutr. 2014 Sep; 5(5):561-2.
Score: 0.022
-
Reduced risk of liver-function-test abnormalities and new gallstone formation with weight loss on 3350-kJ (800-kcal) formula diets. Am J Clin Nutr. 1994 Aug; 60(2):249-54.
Score: 0.022
-
Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998 Nov 11; 280(18):1596-600.
Score: 0.007